|
|
Article: Sirion Therapeutics Initiates Two Phase III Clinical Trials.
- Article from:
- PR Newswire
- Article date:
- May 1, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., May 1 /PRNewswire/ -- Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced today that it has initiated new phase III clinical programs for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).
The two new clinical programs are designed to evaluate ST-601 (difluprednate) as a potential therapy for the treatment of anterior uveitis and ST-603 (cyclosporine) as a potential therapy for the treatment of dry eye syndrome. The addition of these clinical programs brings the company's active clinical programs to five. Sirion's aim is to provide a diverse product offering for the treatment of ...
Related newspaper, magazine, and journal articles:
|
|
Article: Sirion Therapeutics New Drug Application for ...
PR Newswire;
January 26, 2009 ;
700+ words
... ... Jan. 26 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic ... and Drug Administration (FDA). Sirion Therapeutics is seeking approval for ganciclovir ... explained Barry Butler, CEO of Sirion Therapeutics. "If approved by the FDA, ganciclovir ...
|
|